Insurance companies' perspectives on the orphan drug pipeline

American Health and Drug Benefits

Volumn 6, Issue 9, 2013, Pages

  Handfield, Robert ^a   Feldstein, Josh ^b  

^a NORTH CAROLINA STATE UNIVERSITY   (United States)

^b Center for Applied Value Analysis   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ORPHAN DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; CLINICAL PHARMACY; CLINICAL PRACTICE; COST EFFECTIVENESS ANALYSIS; CYSTIC FIBROSIS; DRUG LEGISLATION; FOOD AND DRUG ADMINISTRATION; GOVERNMENT; HEALTH CARE POLICY; HEALTH INSURANCE; HEALTH SURVEY; HUMAN; MEDICAL DECISION MAKING; MELANOMA; METHODOLOGY; OVARY CANCER; PANCREAS CANCER; PRACTICE GUIDELINE;

EID: 84894040406     PISSN: 19422962     EISSN: 19422970     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Pollack A. States seek curb on patient bills for costly drugs. New York Times. April 12, 2012. www.nytimes.com/2012/04/13/health/states-seek-to-curb-exorbitant-drug-costs-incurred-by-patients.html?pagewanted=all&_r=0. Accessed November 11, 2012.
2. Denis A, Mergaert L, Foster C, et al. Orphan diseases and orphan medicines: a Belgian and European study. J Pharm Belg. 2009;(4):131-137.
3. Pharmaceutical Research and Manufacturers of America. Orphan drugs in development for rare diseases. Report. February 2011. www.phrma.org/sites/default/files/pdf/rarediseases2011.pdf. Accessed November 11, 2012.
4. Brewer GJ. Drug development for orphan diseases in the context of personalized medicine. Transl Res. 2009;154:314-322.
5. National Institutes of Health; National Center for Advancing Translational Sciences. FAQ about rare diseases. www.ncats.nih.gov/about/faq/rare/rare-faq.html. Accessed November 11, 2013.
6. National Institute for Clinical Excellence. Ultra orphan drugs. NICE Citizens Council Report. November 2004. www.nice.org.uk/media/065/85/Citizens_Council_ Ultraorphan.pdf. Accessed November 11, 2013.
7. US Food and Drug Administration. Total number of orphan drug designation reviews completed in the month. Fiscal year 2013. Current as of June 30, 2013. www.accessdata.fda.gov/FDATrack/track?program=osmp&id=OSMP-OOPD-Total-number-orphan- drug-designation-reviews-completed&fy=2013. Accessed November 11, 2013.
8. Braun MM, Faraq-El-Massah S, Xu K, Coté TR. Emergence of orphan drugs in the United States: a quantitative assessment of the first 25 years. Nat Rev Drug Discov. 2010; 9:519-522.
9. Denis A, Mergaert L, Fostier C, et al. A comparative study of European rare disease and orphan drug markets. Health Policy. 2010;97:173-179.
10. Brewer GJ. Fundamental problems lie ahead in the drug discovery and commercialization process: restructuring of the pharmaceutical industry and an improved partnership with academia are required. J Investig Med. 2006;54:291-302.
11. Whalen J. Gene-therapy approval marks major milestone. Wall Street Journal. Updated November 2, 2012. http://online.wsj.com/article/SB10001424052970203707604578095091940871524.html. Accessed November 11, 2012.
12. Hughes D. Rationing of drugs for rare diseases. Pharmacoeconomics. 2006;24:315-316.
13. Hyde R, Dobrovolny D. Orphan drug pricing and payer management in the United States: are we approaching the tipping point? Am Health Drug Benefits. 2010; 3(1):15-23.
14. National Institute for Health and Clinical Excellence. Appraising orphan drugs. Draft v3. March 16, 2006. www.nice.org.uk/niceMedia/pdf/smt/120705item4.pdf. Accessed November 11, 2012.
15. DeNavas-Walt C, Proctor BD, Smith JC; For the US Census Bureau. Income, poverty, and health insurance coverage in the United States: 2012. Current population reports. September 2013. www.census.gov/prod/2013pubs/p60-245.pdf. Accessed November 14, 2013.
16. O'Neal PV, Ozcan YA, Ma Y. Benchmarking mechanical ventilation services in teaching hospitals. J Med Syst. 2002;26:227-240.
17. Ozcan YA. Physician benchmarking: measuring variation in practice behavior in treatment of otitis media. Health Care Manag Sci. 1998;1:5-17.
18. Centers for Medicare & Medicaid Services. Medicaid Drug Rebate Program. November 5, 2013. www.medicaid.gov/Medicaid-CHIP-Program-Information/By-Topics/Benefits/Prescription-Drugs/Medicaid-Drug-Rebate-Program.html. Accessed November 14, 2013.